بدائل البحث:
fold decrease » fold increase (توسيع البحث), fold increased (توسيع البحث)
non decrease » nn decrease (توسيع البحث), point decrease (توسيع البحث), note decreased (توسيع البحث)
a decrease » _ decrease (توسيع البحث), _ decreased (توسيع البحث), _ decreases (توسيع البحث)
a fold » 5 fold (توسيع البحث), _ fold (توسيع البحث), 2 fold (توسيع البحث)
a non » _ non (توسيع البحث)
fold decrease » fold increase (توسيع البحث), fold increased (توسيع البحث)
non decrease » nn decrease (توسيع البحث), point decrease (توسيع البحث), note decreased (توسيع البحث)
a decrease » _ decrease (توسيع البحث), _ decreased (توسيع البحث), _ decreases (توسيع البحث)
a fold » 5 fold (توسيع البحث), _ fold (توسيع البحث), 2 fold (توسيع البحث)
a non » _ non (توسيع البحث)
-
141
-
142
-
143
-
144
-
145
-
146
-
147
-
148
-
149
-
150
Upcycling of Postconsumer Recyclate Polypropylene into Low Warping and High Toughness 3D Printable Filaments
منشور في 2025"…Polypropylene (PP) is widely used in commodity applications owing to its chemical stability, mechanical properties and low cost. However, almost 50% of the produced PP ends up as postconsumer waste (PCW) within a short period of usage. …"
-
151
Upcycling of Postconsumer Recyclate Polypropylene into Low Warping and High Toughness 3D Printable Filaments
منشور في 2025"…Polypropylene (PP) is widely used in commodity applications owing to its chemical stability, mechanical properties and low cost. However, almost 50% of the produced PP ends up as postconsumer waste (PCW) within a short period of usage. …"
-
152
-
153
-
154
-
155
The m<sup>6</sup>A peak of 3’UTR of TLR4 mRNA decreases significantly in METTL14-knockdown PK-15 cells.
منشور في 2024"…<p>(A) The m<sup>6</sup>A peak marked in green is decreased in the 3’UTR of TLR4, TLR6, MYD88, TRIF, and other 7 genes from m<sup>6</sup>A-seq data in METTL14-knockdown PK-15 cells infected with CSFV (MOI = 1). …"
-
156
-
157
-
158
-
159
Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc
منشور في 2025"…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …"
-
160